Percutaneous cardiac assist devices compared with surgical hemodynamic support alternatives
Authors:
- 13 January 2014
- journal article
- research article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 83 (6) , E183-E192
Abstract
Objectives: This study evaluates the cost‐effectiveness of percutaneous cardiac assist device (pVAD) therapy in the emergent setting compared with traditional surgical hemodynamic support alternatives. Background: Previous research has demonstrated the cost‐effectiveness of pVAD hemodynamic support for patients undergoing high‐risk percutaneous coronary intervention. For patients in cardiogenic shock (CS), use of pVAD therapy has been shown to reduce length of stay (LOS). Methods: National utilization and outcome data from the 2010–2011 MedPAR and state‐sponsored all‐payer databases were collected for patients with an acute myocardial infarction complicated by CS who were treated with either a pVAD (n = 883) or with traditional surgical hemodynamic support alternatives (ECMO and extracorporeal VAD) (n = 305). Results: Discharge survival was greater with pVADs than with surgical alternatives (56% vs. 42%, P < 0.001) and was achieved with a strong trend toward reduced LOS (13.2 and 17.9 days, respectively, P = 0.055) and a significantly lower cost of the index admission ($90,929 and $144,257, respectively, P < 0.001). Cost‐effectiveness analysis based on the national data demonstrated that pVAD achieved improved outcomes at lower cost. Data were also collected for similar patients who underwent protocol‐guided pVAD therapy (using Impella 2.5) at PinnacleHealth, between 2009 and 2011 (n = 30). At this site, the survival rate increased to 60%, length of hospitalization was shortened to 6 days, and admission costs were lowered to $53,850 relative to the surgical alternatives strategy. Conclusions: For patients in CS requiring emergent hemodynamic support, pVAD therapy offers a less invasive alternative that can be deployed sooner, resulting in better outcomes, shorter LOS, lower costs and with no incremental cost, and a survival benefit when compared with traditional surgical hemodynamic support alternatives. PVAD therapy (and Impella 2.5 in particular) is emerging as a dominant strategy for this challenging patient population.Keywords
This publication has 44 references indexed in Scilit:
- The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: Executive summaryThe Journal of Heart and Lung Transplantation, 2013
- Recommendations for the Use of Mechanical Circulatory Support: Device Strategies and Patient SelectionCirculation, 2012
- A Prospective, Randomized Clinical Trial of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous Coronary InterventionCirculation, 2012
- Peripheral Extracorporeal Membrane Oxygenation System as Salvage Treatment of Patients With Refractory Cardiogenic Shock: Preliminary Outcome EvaluationArtificial Organs, 2012
- Cost-Effectiveness Analysis of Continuous-Flow Left Ventricular Assist Devices as Destination TherapyCirculation: Heart Failure, 2012
- Heart Disease and Stroke Statistics—2012 UpdateCirculation, 2012
- Thirty-Year Trends (1975 to 2005) in the Magnitude of, Management of, and Hospital Death Rates Associated With Cardiogenic Shock in Patients With Acute Myocardial InfarctionCirculation, 2009
- Cost-effectiveness of Ventricular Assist Device Use in the United Kingdom: Results From the Evaluation of Ventricular Assist Device Programme in the UK (EVAD-UK)The Journal of Heart and Lung Transplantation, 2006
- A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shockAmerican Heart Journal, 2006
- The Value of Medical Spending in the United States, 1960–2000New England Journal of Medicine, 2006